Logo
x

Search

Subscribe Now

Metastatic Pancreatic Cancer

AstraZeneca and MSD's Lynparza (olaparib) Receives EC's Approval for BRCA-Mutated Metastatic Pancreatic Cancer

AstraZeneca and MSD's Lynparza (olaparib) Receives EC's Approval for BRCA-Mutated Metastatic Pancreatic Cancer

  • July 8, 2020
AstraZeneca and Merck &Co's Lynparza Receive the US FDA's Approval as a 1L Maintenance Treatment of Germline BRCA-Mutated Metastatic Pancreatic Cancer

AstraZeneca and Merck &Co's Lynparza Receive the US FDA's Approval as a 1L Maintenance Treatment of Germline BRCA-Mutated Metastat...

  • December 30, 2019
BioLineRx Reports Results of BL-8040 in Combination with Keytruda (pembrolizumab) in P-IIb Trial for Patients with Metastatic Pancreatic Cancer

BioLineRx Reports Results of BL-8040 in Combination with Keytruda (pembrolizumab) in P-IIb Trial for Patients with Metastatic Panc...

  • November 6, 2019
Halozyme to Discontinue its P-III HALO-301 Study of PEGPH20 for the Treatment of Metastatic Pancreatic Cancer

Halozyme to Discontinue its P-III HALO-301 Study of PEGPH20 for the Treatment of Metastatic Pancreatic Cancer

  • November 4, 2019
Lilly Reports Results Pegilodecakin + Folfox in P-III SEQUOIA Study for Metastatic Pancreatic Cancer

Lilly Reports Results Pegilodecakin + Folfox in P-III SEQUOIA Study for Metastatic Pancreatic Cancer

  • October 16, 2019
Rafael Pharmaceuticals' Devimistat (CPI-613) Receives EMA's ODD for R/R Acute Myeloid Leukemia (AML) and Metastatic Pancreatic Cancer (mPC)

Rafael Pharmaceuticals' Devimistat (CPI-613) Receives EMA's ODD for R/R Acute Myeloid Leukemia (AML) and Metastatic Pancreatic Can...

  • January 11, 2019
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.